The Quantellect read.As of Nov 19, 2026, 7 active firms cover Arcutis Biotherapeutics Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $34.00 to $48.00, a moderate spread. The average target of $39.14 sits 42% above the current $27.61. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 32% this year and 30% next, consensus EPS building from about $0.06 next quarter toward $1.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$39.14
+41.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $27.61 current
Highest Target$48.00
Average Target$39.14
Lowest Target$34.00
Detailed analyst forecasts for ARQT
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate ARQT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ARQT EPS & revenue forecast
EPS · NEXT QUARTER
$0.06
Range $-0.09 – $0.14 · 4 analysts · -161% YoY
Next period, 4 analysts expect Arcutis Biotherapeutics Inc to earn $0.06 a share (range $-0.09 – $0.14), versus $-0.09 a year earlier. Full-year consensus is $0.33, growing to $1.09 the year after.
REVENUE · NEXT QUARTER
$145.5M
Range $133.8M – $152.1M · 4 analysts · +30% YoY
Revenue is expected to reach $145.5M (range $133.8M – $152.1M), +30.0% year-over-year. Full-year consensus is $542.2M, rising to $703.0M next year.
Top analysts covering Arcutis Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARQT.
#1
Serge Belanger
Needham · Rank #129
Buy
$40.00+44.9% to target
Overall win rate
46%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #312
Buy
$34.00+23.1% to target
Overall win rate
35%
+ Follow
#3
Seamus Fernandez
Guggenheim
Buy
$44.00+59.4% to target
Coverage
—
+ Follow
#4
UE
Uy Ear
Mizuho
Buy
$35.00+26.8% to target
Coverage
—
+ Follow
#5
Tyler Van Buren
TD Cowen
Buy
$35.00+26.8% to target
Coverage
—
+ Follow
ARQT stock forecast FAQ
What is ARQT's average 12-month price target?+
The 7 active firms with a live target average $39.14 for Arcutis Biotherapeutics Inc over the next 12 months, ranging from a $48.00 high to a $34.00 low, as of Nov 19, 2026.
Is ARQT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ARQT?+
The Street-high target is $48.00 (Cantor Fitzgerald), and the Street-low is $34.00 (HC Wainwright & Co.). The average of all 7 active-firm targets is $39.14.
How many active Wall Street firms cover ARQT?+
7 active firms have a recognized rating on Arcutis Biotherapeutics Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ARQT?+
Among analysts who currently cover ARQT, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #129). Their current call is Buy with a $40.00 target.
What is Arcutis Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.06 per share (range $-0.09 – $0.14) across 4 analysts. Full-year EPS is projected at $0.33, rising to $1.09 the following year.
How much revenue is Arcutis Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $145.5M (range $133.8M – $152.1M). Full-year revenue is projected at $542.2M, growing to $703.0M next year.
Have analysts been upgrading or downgrading ARQT lately?+
As of Nov 19, 2026, 7 of 7 active firms rate ARQT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARQT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.